openPR Logo
Press release

Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from ~USD 310 Million in 2024 | DelveInsight

10-07-2025 06:03 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Pheochromocytomas and Paragangliomas Market

Pheochromocytomas and Paragangliomas Market

The pheochromocytomas and paragangliomas market is poised for robust expansion, primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options by key pheochromocytoma companies, such as Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.

DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast - 2034"[https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] report delivers comprehensive insights into Pheochromocytomas and Paragangliomas market, including historical and forecasted epidemiology, current treatment paradigms, and emerging therapies across the 7MM, which include, US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report presents a detailed analysis of pheochromocytomas market trends, therapeutic landscapes, and unmet needs, providing valuable strategic insights for stakeholders in this specialized neuroendocrine tumor market.

The pheochromocytomas and paragangliomas market is poised for significant expansion, with the market size across the 7MM estimated at approximately USD 310 million in 2024. This growth trajectory is primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options targeting specific molecular pathways. The US currently holds the largest pheochromocytoma market share, accounting for approximately USD 190 million in 2024, with promising growth expected in the coming decade due to favorable reimbursement policies and rapid adoption of innovative treatment modalities.

Download the Pheochromocytomas and Paragangliomas Market report to understand which factors are driving the PCPG therapeutic market @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

The pheochromocytomas and paragangliomas epidemiological landscape reveals approximately 5K incident cases across the 7MM in 2024, with projections indicating sustained growth throughout the forecast period. Genetic analysis has become increasingly important in pheochromocytomas and paragangliomas management, with nearly 75% of US cases showing germline or somatic mutations in 2024. Among the EU4 and UK markets, which collectively reported approximately 2K incident cases in 2024, Germany accounted for the highest disease burden, while Spain demonstrated the lowest incidence. Japan shows a noteworthy pattern with localized pheochromocytoma cases significantly outnumbering metastatic presentations.

Discover evolving trends in the Pheochromocytomas and Paragangliomas patient pool forecasts @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

The report also analyses the current and emerging pheochromocytoma and paraganglioma treatment landscape. The current therapeutic landscape varies based on disease staging and functional status. For localized tumors, radical surgical resection remains the cornerstone of treatment, representing the only potentially curative intervention. The metastatic pheochromocytoma treatment paradigm has evolved toward a multidisciplinary approach encompassing debulking surgery, chemotherapy (particularly the cyclophosphamide, vincristine, and dacarbazine regimen), tyrosine kinase inhibitors, immunotherapies, and advanced radionuclide therapies. Radionuclide injection, a targeted treatment option, is also used for pheochromocytoma and paraganglioma treatment, especially in metastatic or inoperable cases.

Key marketed treatments include DEMSER (metyrosine) from Bausch Health (NYSE: BHC) and Ono Pharmaceutical (TYO: 4528). This oral tyrosine hydroxylase inhibitor remains an important option for preoperative preparation and chronic management of malignant pheochromocytoma. In July 2020, the FDA approved Amneal Pharmaceuticals' generic version of DEMSER oral capsules.

The treatment landscape has faced challenges, including the AZEDRA discontinuation in 2023, due to commercial non-viability. AZEDRA, manufactured by Lantheus Holdings (NASDAQ: LNTH), was approved by the FDA in 2018 based on Study IB12 B.

Despite the challenges associated with drug development for ultra-rare diseases, the pheochromocytomas and paragangliomas pipeline demonstrates significant innovation, with several promising candidates advancing through clinical development.

In January 2025, the FDA accepted for Priority Review a supplemental New Drug Application for Merck's WELIREG (belzutifan) for treating adult and pediatric patients with advanced, unresectable, or metastatic pheochromocytomas and paragangliomas. Welireg MOA involves blocking HIF-2α, which helps tumors grow in low-oxygen conditions. With a PDUFA date of May 26, 2025, WELIREG is positioned to potentially capture substantial market share upon approval.

Other notable emerging therapies include Chimerix's ONC201, a first-in-class small molecule imipridone that selectively binds to dopamine receptor D2 and mitochondrial protease ClpP. ONC201 demonstrated a 50% objective response rate in paraganglioma during Phase II studies. Novartis (SWX: NOVN) is advancing LUTATHERA, a radiopharmaceutical that targets somatostatin receptors.
Additionally, in November 2024, Perspective Therapeutics (NYSE: CATX) presented promising initial results from its Phase I/IIa clinical trial of VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium.

Discover recent advancements in the Pheochromocytomas and Paragangliomas treatment landscape @ https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

The therapeutic landscape is increasingly focusing on targeted approaches based on tumor genetic profiles, with treatments tailored to specific molecular clusters. These include radionuclide therapies with SSTR2 agonists/antagonists, cold SSTR2 analogs, HIF-2α inhibitors, and novel DRD2 and ClpP agonists. This precision medicine approach represents a paradigm shift from traditional symptom management to molecularly targeted interventions that address the underlying pathophysiology of these rare neuroendocrine tumors.
Despite therapeutic advances, significant challenges remain in pheochromocytomas and paragangliomas management, including the heterogeneity of tumor behavior, limited treatment options for metastatic disease, and the need for improved biomarkers to guide therapy selection. The market is expected to witness continued growth driven by increased disease recognition, expanded genetic testing, and the introduction of innovative treatment modalities that address current unmet needs in this specialized oncology segment.

Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. PCPG MARKET OVERVIEW AT A GLANCE
5. KEY EVENTS
6. EPIDEMIOLOGY AND MARKET METHODOLOGY
7. PCPG BACKGROUND AND OVERVIEW
8. PCPG TREATMENT AND MANAGEMENT
9. PCPG EPIDEMIOLOGY AND PATIENT POPULATION
10. PCPG PATIENT JOURNEY
11. PCPG MARKETED DRUGS
12. PCPG DISCONTINUED PRODUCT
13. PCPG EMERGING DRUGS
14. PCPG: SEVEN MAJOR MARKET ANALYSIS
15. PCPG UNMET NEEDS
16. SWOT ANALYSIS
17. KOL VIEWS
18. MARKET ACCESS AND REIMBURSEMENT
19. APPENDIX
20. DELVEINSIGHT CAPABILITIES
21. DISCLAIMER
22. ABOUT DELVEINSIGHT

Arpit Anand
info@delveinsight.com
+14699457679

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from ~USD 310 Million in 2024 | DelveInsight here

News-ID: 4212507 • Views:

More Releases from DelveInsight Business Research

Dry AMD Market Set for Significant Transformation Through 2034, Driven by Novel Therapeutic Approaches and Rising Disease Awareness | DelveInsight
Dry AMD Market Set for Significant Transformation Through 2034, Driven by Novel …
The dry age-related macular degeneration treatment market is experiencing unprecedented growth, driven by increasing disease awareness, rising prevalence of age-related eye conditions, and breakthrough therapeutic developments from major pharmaceutical companies, including Alkeus Pharmaceuticals, Cognition Therapeutics, Dobecure, Evergreen Therapeutics, InflammX Therapeutics, Lineage Cell Therapeutics, Luxa Biotechnology, Regenerative Patch Technologies, Amgen Inc., AstraZeneca, Bayer AG, Biogen, Boehringer Ingelheim, Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer Inc., actively pursuing innovative treatment solutions. DelveInsight's
Celiac Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent M&A and Advancing Clinical Development Pipeline | DelveInsight
Celiac Disease Treatment Market Set for Robust Growth Through 2034, Driven by Re …
The celiac disease treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Entero Therapeutics, Amgen/Provention Bio, Takeda, and Sanofi, among others. DelveInsight's "Celiac Disease Market Insight, Epidemiology And Market Forecast - 2034" report delivers an in-depth understanding of the celiac disease treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France,
Urticaria Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Approvals, Future Outlook by DelveInsight
Urticaria Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA Ap …
As per DelveInsight's assessment, globally, Urticaria pipeline constitutes 20+ key companies continuously working towards developing 25+ Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Urticaria Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Urticaria Market. The Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from
Artificial Intelligence (AI) in Remote Patient Monitoring Market is expected to reach USD 13,126.80 million by 2032 | DelveInsight
Artificial Intelligence (AI) in Remote Patient Monitoring Market is expected to …
DelveInsight's "Artificial Intelligence (AI) in Remote Patient Monitoring Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Remote Patient Monitoring companies actively working in the market. According to DelveInsight's analysis, The AI in Remote Patient Monitoring market, valued at USD 1,926.51 million in

All 5 Releases


More Releases for PCPG

Pheochromocytomas and Paragangliomas (PPGL) Market to Set Phenomenal Growth From …
Pheochromocytomas and Paragangliomas (PPGL) Market Outlook 2024-2034: Rising Awareness and Targeted Therapies Drive Growth Introduction Pheochromocytomas and paragangliomas (collectively known as PPGL or PCPG) are rare neuroendocrine tumors that originate from chromaffin cells in the adrenal medulla or extra-adrenal paraganglia. While pheochromocytomas arise in the adrenal glands, paragangliomas occur in various parts of the body including the abdomen, chest, and head-and-neck region. Although rare, these tumors can be life-threatening if untreated, often associated
Idiopathic Interstitial Pneumonia (IIP) Market Growth, Applications, Innovations …
Introduction Idiopathic interstitial pneumonias (IIPs) are a group of rare, chronic lung disorders characterized by varying degrees of inflammation and fibrosis of the lung interstitium. They include conditions such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptogenic organizing pneumonia (COP), desquamative interstitial pneumonia (DIP), and acute interstitial pneumonia (AIP). Among these, IPF is the most common and severe form, leading to progressive scarring
Pheochromocytomas and Paragangliomas Market Forecast - Unlocking Rare Tumor Insi …
Pheochromocytomas and Paragangliomas (PCPG) are rare neuroendocrine tumors originating from chromaffin cells of the adrenal medulla and extra-adrenal paraganglia, respectively. While pheochromocytomas typically arise in the adrenal glands, paragangliomas can develop anywhere along the sympathetic and parasympathetic chains. Though generally benign, these tumors can secrete excess catecholamines, leading to severe cardiovascular complications such as hypertension, arrhythmias, and even stroke, if not diagnosed and managed promptly. DelveInsight's comprehensive report, "Pheochromocytomas and Paragangliomas
Pheochromocytomas and Paragangliomas Market to Grow Significantly by 2034, from …
The pheochromocytomas and paragangliomas market is poised for robust expansion, primarily driven by increasing diagnostic capabilities, rising disease awareness, and the anticipated launch of novel therapeutic options by key pheochromocytoma companies, such as Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others. DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights into Pheochromocytomas and Paragangliomas market, including historical and forecasted epidemiology, current treatment
Pheochromocytomas and Paragangliomas Treatment Market Size in 7MM is expected to …
DelveInsight's "Pheochromocytomas and Paragangliomas Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Pheochromocytomas and Paragangliomas, historical and forecasted epidemiology as well as the Pheochromocytomas and Paragangliomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover which therapies are expected to grab the Pheochromocytomas and Paragangliomas Market Share @ Pheochromocytomas and Paragangliomas Market Outlook- https://www.delveinsight.com/sample-request/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the
Pheochromocytomas Market Statistics Expected to Experience Major Growth by 2032, …
DelveInsight's "Pheochromocytomas Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pheochromocytomas, historical and forecasted epidemiology as well as the Pheochromocytomas market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Pheochromocytomas, offering comprehensive insights into the Pheochromocytomas revenue trends, prevalence, and treatment landscape. The report delves into key Pheochromocytomas